Strides Shasun gets US health regulator tentative nod for HIV treatment drug
NEW DELHI: Strides Shasun said it has received tentative approval from the US health regulator for Efavirenz tablets used in treating human immunodeficiency virus (HIV) infection.
The company has received tentative approval from the US Food and Drug Administration (USFDA) for Efavirenz tablets USP, 600 mg, Strides Shasun said in a regulatory filing.
The final approval will be received after patent expiry in August 2018, it added.
According to IMS sales data, the US market for Efavirenz tablets is around USD 150 million.
The company will manufacture the product at its oral dosage facility in Bengaluru.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd